The cash-strapped biotech adds Car-T projects but tries to avoid a lawsuit.
ApexOnco Front Page
Recent articles
Meanwhile, Zai Lab faces delays in its pivotal DLL3 trial.
The restructured biotech’s new lead project enters phase 1.
The company will imminently start its third pivotal trial of PF-08634404.
The Rainfol-04 trial in platinum-sensitive ovarian cancer will start next year.
The company ditches lorigerlimab in prostate cancer.
But the Day One deal is still 29% below where the shares stood at the start of this year.
New detalimogene bladder cancer data send the minnow’s stock up 47%.
